Home of Heart Recovery
Impella heart pumps have been shown to contribute to improvement in high-risk PCI, survival in cardiogenic shock, and cost-effective therapy design.
Learn more about the available clinical evidence on Impella Heart Pumps in the field of Protected PCI and cardiogenic shock on this page. Discover multimedia articles on the indication fields and our peer-to-peer community CAMP.
-
13
include Impella heart pumps (nationally and internationally)
-
2x
Higher survival rate during ECMO therapy with Impella unloading (ECpella)9
-
76%
Reduction of heart failure symptoms NYHA Class III/IV symptom improvement in HRPCI patients1,3
EF Improvement Following Contemporary High-Risk PCI
RESTORE EF shows EF improved by 29% from overall baseline of 35% to 45% in high-risk PCI patients supported with Impella® heart pumps.
Clinical Evidence about Impella Heart Pumps
Discover Additional Ressources
Learn more about the use of the Impella heart pump in cardiogenic shock.
Download NowLearn more about the INOVA Heart & Vascular Institute's Protected PCI algorithm.
Download Now
Improved Patient Management Through Continuous Product Innovation
Abiomed is constantly developing its product portfolio to achieve the best possible outcome for patients and users - in line with our mission: Patients first!
These product innovations and enhancements include not only changes to our heart pumps, but also software enhancements to the Automated Impella Controller (AIC) in the form of more accurate alarms, expanded metrics, and easier set-up.
-
10
Product innovations to improve user-friendliness and patient management
-
400+
Hospitals already benefit from Impella Connect®
-
9%
Reducation of bleeding through continuous improvements to the technology
Impella 5.5® with SmartAssist® Heart Pump
Minimally invasive heart pump for maximum hemodynamic support through complete unloading
Impella CP® with SmartAssist® Heart Pump
The next generation heart recovery technology
CAMP - Community is Key
Exchange ideas with colleagues, identify potential treatment challenges, and leverage the power of the CAMP community to improve the management of patients with acute heart failure and treating high-risk PCI patients. Designed for all levels of clinical expertise in the management of coronary artery disease, the CAMP platform provides continuous learning and sharing on one platform.
Education Library - Education on Demand
Discover education about Impella® devices wherever you want and whenever you want.
Contact Us
Do you want to learn more about Impella heart pumps or contact your dedicated Abiomed sales representative? Get in touch with us.
References
- O’Neill, et al. (2012). Circulation, 126 (14), 1717-1727.
- Burzotta, et al. (2019). Journal of Interventional Cardiology, 1–10.
- Wollmuth, J., Patel, M. et al. (2022). JSCAI, 100350. https://doi.org/10.1016/j.jscai.2022.100350.
- O’Neill, et al. (2020). TCT Connect 2020 Presentation
- Ako, et al. (2022). TCT Symposium.
- gemäß Fallpauschalen-Katalog 2023
- Dangas, et al. (2014). Am J Cardiol, 113 (2), 222-8.
- Basir, et al. (2021). SCAI Scientific Sessions
- Pappalardo, et al. (2017). Eur J Heart Fail, 19 (3), 404-412.
- O’Neill. (2018). Acute Coronary Syndromes, Cardiogenic Shock, and Hemodynamic Support, TCT
- Tehrani et al. (2019), JACC 73 (13), 1659-69
- FDA-PMA-Antrag, Daten in den Akten (transfusionspflichtige Blutungen)
- Al‐khadra, et al. (2020). Catheter Cardiovasc Interv, 95(3), 503-512.
- O'Neill, W., et al. (2022). American Heart Journal, 248, 139-149.
- verfügbare US-Veröffentlichungen und FDA-Studien mit gerätespezifischen Raten schwerer Blutungen oder transfusionspflichtigen Blutungen
- Iannaccone et al. (2022). Cardiovasc Revasc Med., DOI: 10.1016/j.carrev.2021.10.001
- Panoulas et al. (2021) Rev Cardiovasc Med., DOI: 10.31083/j.rcm2204154
- PROTECT II FDA PMA-Daten. Hypotoniebedingtes Ereignis definiert als MAP < 65 mmHg
- Chieffo, Tarantini et al. The IMP-IT Registry; EuroIntervention. 2020;15:e1343-e1350
- Aurigemma et al. (2021) JACC: CARDIOVASCULAR INTERVENTIONS VOL. 14, NO. 6, MARCH 22, 2021:709 – 2 1
- Gemäß Daten des DRG-Datenbrowsers vom InEK für den Zeitraum Januar bis Mai 2022
NPS-3503